Investing.com — shares jumped after the Swiss skincare company posted a sharp rise in first-quarter sales and signalled it could weather the impact of U.S. tariffs, easing investor concerns.
The stock was up 4.6% by 07:59 GMT.
The Zug-based company reported first-quarter sales of $1.47 billion, up 25.5% on a constant-currency basis, with growth driven predominantly by volume and supported by positive price and mix effects.
U.S. sales were a key driver, surging 41.5% year-on-year.
By segment, Therapeutic Dermatology led the way with growth of 71.3%, followed by Dermatological Skincare at 17.0% and Injectable Aesthetics at 13.1%.
On tariffs, Galderma said its exposure “remains manageable” for the year. Full-year guidance now factors in the already-assumed 15% U.S. tariff on imports of Sculptra and Restylane, as well as the expected effects of the U.S. administration’s recent proclamation on pharmaceutical imports, the company said.
Galderma reaffirmed its 2026 outlook, targeting net sales growth of 17% to 20% at constant currency and a core EBITDA margin of around 26%.
“Based on the strong start to the year, the guidance is increasingly being de-risked with confidence to navigate a volatile environment,” it said.